J. Hearing

Associate Professor

Department of Microbiology and Immunology
Ph.D., Stony Brook University, 1984



(631) 632-8778
(631) 632-9162




Development of Antiviral Drugs to Combat COVID-19

Immunization is the front-line defense against viral infections, however antiviral drugs are also needed to prevent or treat disease caused by viruses for which a vaccine is not yet available and for individuals who have not been immunized or did not develop protective immunity following vaccination. Enormous effort is underway to identify additional antiviral agents that may be used alone or in combination therapy with the currently licensed drugs remdesevir and Paxlovid. We have found that interferon lambda can reduce morbidity and mortality in an animal model of infection and are currently testing candidate antiviral compounds in collaboration with other researchers at Stony Brook University.